ELI LILLY

Advertisement
Dec 01 2025HEALTH

Zepbound Gets a Price Cut: What This Means for You

Eli Lilly has made a big move to make its weight-loss drug, Zepbound, more affordable. They've lowered the price of single-dose vials, hoping more people can get their hands on it. Now, the starting dose is $299 a month, down from $349. Higher doses are also cheaper now, with the 5 mg dose at $399 a

reading time less than a minute
Aug 24 2025HEALTH

A New Player in the Weight Loss Pill Game

Eli Lilly is making waves in the weight loss drug market with its new obesity pill, orforglipron. This pill is set to compete with Novo Nordisk's oral semaglutide, which has shown promising results. Both drugs work by mimicking a gut hormone called GLP-1 to help control appetite and blood sugar leve

reading time less than a minute
Apr 24 2025HEALTH

Pharmaceutical Giant Takes Legal Action Against Telehealth Firms Over Weight Loss Drug

A major pharmaceutical company is taking legal action against several telehealth companies for allegedly selling unauthorized versions of a popular weight loss drug. This drug, known for its active ingredient, has been in high demand. The company behind the drug, Eli Lilly, is suing four telehealth

reading time less than a minute
Feb 27 2025BUSINESS

U. S. Manufacturing Boost: Eli Lilly's Big Bet

Eli Lilly has just announced a massive investment of $27 billion to construct four new manufacturing sites across the U. S. This move is driven by the surging demand for their popular weight loss and diabetes injections, as well as their plans to develop new drugs for various conditions. This invest

reading time less than a minute
Jan 14 2025BUSINESS

Why Eli Lilly's Weight-Loss Drug Sales Missed the Mark

Eli Lilly, a company based in Indianapolis, recently faced a blow when its stock prices dipped. The reason? Their weight-loss drugs, Zepbound and Mounjaro, didn't sell as well as expected. The company predicted they'd make about $13. 5 billion in the December quarter, which is less than what experts

reading time less than a minute
Nov 19 2024FINANCE

Health Stocks: Opportunities Amid Uncertainty

The U. S. healthcare sector has been through a rough patch since the presidential election, with stocks like Danaher and Eli Lilly taking a hit. This uncertainty stems from President-elect Trump's choice for the Secretary of Health and Human Services, Robert F. Kennedy Jr. , known for his skepticism

reading time less than a minute
Oct 30 2024FINANCE

Eli Lilly's stocks take a hit: Should you worry?

Eli Lilly's recent earnings report wasn't great, with stocks falling after missing growth targets. But don't panic just yet. The dip could be a chance to buy. Think of it like a rollercoaster: there are ups and downs, but the long-term view is what counts. The company had a messy quarter, but it's a

reading time less than a minute
Oct 03 2024NATION

Eli Lilly to build $4. 5 billion research and manufacturing center

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's ob

reading time less than a minute
Sep 17 2024ENVIRONMENT

A New Horizon for Offshore Wind Power in the Gulf of Maine

The US Department of Interior has set an auction date of October 29th for the first-ever sale of offshore wind energy leases in the Gulf of Maine. This significant move marks a major step forward in the country's efforts to transition to cleaner, renewable energy sources. The auction, which includes

reading time less than a minute
Sep 16 2024FINANCE

Cryptocurrency Firms Coinbase and MicroStrategy Share Earnings Results: What Do the Numbers Reveal?

Coinbase and MicroStrategy, two prominent players in the cryptocurrency space, recently released their earnings reports, offering a glimpse into the financial health of these companies. At first glance, it appears that Coinbase has beaten revenue expectations, while MicroStrategy reported a loss. Bu

reading time less than a minute